Moderna, Inc. | MarketScreener
MRNA-4157/V940, an Investigational Personalized MRNA Cancer Vaccine, in Combination With Keytruda , Receives Prime Scheme Designation From the European Medicines Agency for Adjuvant Treatment of... | April 6, 2023
Source: marketscreener.com